3 Great Growth Stocks For Savvy Investors: GlaxoSmithKline plc, Legal & General Group Plc And Sports Direct International Plc

Royston Wild takes a look at the earnings outlook over at GlaxoSmithKline plc (LON: GSK), Legal & General Group Plc (LON: LGEN) and Sports Direct International Plc (LON: SPD).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three London-listed companies set to deliver excellent earnings growth.

GlaxoSmithKline

Considering that GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has been steadily battered by a stream of patent expirations across key products, at first glance the pharma play not be an obvious pick for those seeking reliable earnings growth. Indeed, the prospect of further exclusivity losses are expected to produce yet another annual earnings loss this year, with a 4% dip currently mooted.

Still, I believe that the sales picture is definitely on the up for the Brentford-based firm. Of course the business of drugs testing can often be frustrating and expensive should products fail to make the grade or become subject to severe launch delays.

However, in GlaxoSmithKline’s case the company is chucking vast sums at its pipeline to develop the next generation of revenues drivers and mitigate these problems, achieved through a combination of organic investment, industry synergies like that with Swiss giant Novartis, and a steady conveyor belt of acquisitions.

Consequently GlaxoSmithKline is expected to get back on the right track from next year onwards, and a 4% earnings bounceback is currently projected for 2016. Although the company trades on P/E multiples of 18.2 times and 17.2 times projected earnings for 2015 and 2016 correspondingly — outside the watermark of 15 times or below which signals attractive value — I reckon that the fruits of GlaxoSmithKline’s robust pipeline, not to mention fruits of galloping global drug demand, should drive sales through the roof in coming years and therefore merits this premium.

Legal & General Group

Life insurance leviathan Legal & General (LSE: LGEN) has been a reliable generator of reliable, double-digit earnings growth in the post-recession landscape. And boosted by a renewed focus towards developing regions, not to mention a product portfolio, I believe that this strong momentum is set to reign during the medium term at least.

This view is shared by the City, and Legal & General is expected to generate further growth in the region of 13% for the current 12-month period. And further 9% rise is anticipated for 2016.

These numbers leave the insurer changing hands on a P/E ratio of 15.2 times for 2015, but which slips to just 14 times for next year. With Legal & General’s ability to throw up boatloads of cash also reinforcing its aggressive acquisition drive — indeed, the firm finalised the purchase of New Life Home Finance for £5m earlier this month — I expect new business levels to ignite looking ahead.

Sports Direct International

Like Legal & General, sportswear outlet Sports Direct (LSE: SPD) has a proud record of creating exceptional year-on-year earnings growth for some time now — indeed, the business has seen the bottom line swell at a compound annual growth rate of 26.9% during the past five years alone. With Britain’s fitness craze showing no signs of slowing, I fully expect the trainer and tracksuit specialists to keep enjoying excellent growth.

The abacus bashers agree with my bullish take, and predict that Sports Direct will see earnings advance 16% for the year closing April 2015. And further improvements of 17% and 13% are pencilled in for fiscal 2016 and 2017 correspondingly.

As a result the business deals on P/E multiples of just 15 times for this year and 13.7 times prospective earnings for 2017. With Mike Ashley’s outfit also expanding aggressively in European marketplaces, I expect sales of its cut-price sportswear to continue heading for the stars.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Sports Direct International. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »